Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized Study Evaluating Gemcitabine and Paclitaxel Versus Gemcitabine Alone After FOLFIRINOX Failure or Intolerance in Metastatic Pancreatic Ductal Adenocarcinoma

NCT03943667 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT03943667
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03943667 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized Study Evaluating Gemcitabine and Paclitaxel Versus Gemcitabine Alone After FOLFIRINOX Failure or Intolerance in Metastatic Pancreatic Ductal Adenocarcinoma
Lead sponsor
UNICANCER
Phase
Phase 3
Overall status
Completed
Start date
May 23, 2019
Completion date
April 26, 2022
Enrollment
211 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic adenocarcinoma